Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599009 | 0.86 | PPARG (0.42) | ATMPPARGPPARAACEPTPN1 | |
| SCHEMBL19899292 | 0.86 | ATM (0.41) | ATMHDAC1HDAC6ACE | |
| SCHEMBL30510366 | 0.86 | CTRB1 (0.40) | PPARGPPARAITGA4ITGB1 | |
| SCHEMBL4600067 | 0.86 | CTRB1 (0.40) | PPARGPPARAITGA4ITGB1 | |
| SCHEMBL5407004 | 0.86 | CTRB1 (0.40) | PPARGPPARAITGA4ITGB1 | |
| SCHEMBL4600752 | 0.86 | CTRB1 (0.40) | PPARGPPARAITGA4ITGB1 | |
| SCHEMBL4600305 | 0.86 | PPARG (0.39) | PPARGPPARAITGA4ITGB1 | |
| SCHEMBL1063197 | 0.86 | PPARG (0.39) | PPARGPPARAITGA4ITGB1 | |
| SCHEMBL1054727 | 0.85 | PLA2G10 (0.38) | PPARGPPARAHDAC1HDAC6ITGA4 | |
| SCHEMBL4599268 | 0.85 | ITGA4 (0.35) | SLC7A5ATMPPARGPPARAITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275105-B1 | Heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-05 | — | — | EP | disclosed |
| EP-1499313-B1 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2275105-A1 | Heterocyclic derivatives as opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7041681-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-09 | — | — | US | disclosed |
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | BRESLIN HENRY J | 2006-02-09 | — | — | US | disclosed |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | BRESLIN HENRY J (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1499313-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003092688-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | SLC7A5 1659/4885ATM 4840/4885PPARG 870/4885 |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | OPRL1, OPRK1, OPRD1 | SLC7A5 3621/4885ATM 4836/4885PPARG 609/4885 |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | SLC7A5 1659/4885ATM 4840/4885PPARG 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.